Company: SXTPW
Filing Date: 2025-09-05
Form Type: 424B5
Source: 0001213900-25-085050
Chunk: 32

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-09-05
Form: 424B5
Chunk 32
---
| ● | shares                                                                                     
 of common stock issuable upon the conversion of 76,480 shares of Series A Preferred Stock. |

<div align='center'>S-18

RISK FACTORS</div>

An investment in our common stock or securities convertible or exercisable into our common stock involves a high degree of risk. Before deciding whether to invest in our securities, you should carefully consider the risks described below and those discussed under the caption titled “Risk Factors” in the accompanying base prospectus, our Annual Reports on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and any amendment or update thereto reflected in subsequent filings with the SEC, which are incorporated by reference in this prospectus supplement and the accompanying base prospectus, together with other information in this prospectus supplement, the accompanying base prospectus, the information and documents incorporated by reference herein and therein, and in any free writing prospectus that we have authorized for use in connection with this offering. If any of these risks actually occurs, our business, financial condition, results of operations or cash flow could be seriously harmed. This could cause the trading price of our common stock to decline, resulting in a loss of all or part of your investment.

Risks Related to This Offering

Management will have broad discretion as to the use of the proceeds from this offering, and we may not use the proceeds effectively.

Our management will have broad
discretion with respect to the use of proceeds of this offering, including for any of the purposes described in the section of this prospectus
supplement titled “Use of Proceeds.” You will be relying on the judgment of our management regarding the application of
the proceeds of this offering. The results and effectiveness of the use of proceeds are uncertain, and we could spend the proceeds in
ways that you do not agree with or that do not improve our results of operations or enhance the value of our common stock. Our failure
to apply these funds effectively could have a material adverse effect on our business, delay the development of our product candidates,
and cause the price of our common stock to decline.

Raising additional capital, including as a result of this offering, may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our product candidates.

Until such time, if ever, as
we can generate substantial revenue, we expect to finance our cash needs through a combination of equity offerings and/or debt financings.
To the extent that we raise additional capital through the sale of equity securities,